for Tim, thank call Thanks, this and afternoon. the joining all you
globe. progress second made the we've around the important quarter, franchise DMD the Over growing
In the addition quarter patients. old increased include value two five-year by franchise Emflaza this we have the expanding to to label
of to Translarna to provide Furthermore, following approval with of Translarna in Brazil, Health contract the patients. we completed an Ministry annual
for programs of end platform be for molecule on small treatment NDA We continue a of our Risdiplam, an to advancing including by therapy first in from gene splicing the year deficiency. for track therapies identified two to with product our BLA the the regulatory pipeline submitted AADC our authorities and the a
we stage products options. suffering or vision PTC's five-year for value mission mission, bringing continued programs stakeholders. therapies will clinical disorders fulfilling that we of differentiated of of with reflect By from the our no This described elucidated these treatment all year. our be rare to last creating limited Moving patients to this strategic plan execution commercial
to One patients key of that robust pillar treatments. is to of orphan diversified our platforms one continue products franchise. need multiple our believe key ability across strategic drug is orphan bring PTC's in to differentiators of new build a to to work scientific plan We
products currently across nonsense mutation through, core Our technology, platforms oncology. therapy, five and splicing, programs anti-sense innovative span gene including and read alternative DNA
ensuring patients products sought develop innovative to We against us mechanisms with allow differentiated that unmet intentionally pipeline of targets with that needs. bring to products to diversify medical action high we our
the in Because of we the year, of to the SMA, are plan. for next our product product have launches AADC efforts, therapy gene team's of deficiency. and I'm execution strategic Hattr, for Waylivra over very for Risdiplam FCS, for these now proud the Tegsedi position, four
$X.X of billion, for year based U.S. potential all royalty revenue in is products revenues be excess is potential will already XXXX. In DMD the submitted or which study. are grow of the of dystrophin in on approval and in of to for either streams these approved, XXXX, approval by addition, there outcome for Translarna potential anticipated The this combined of
the was infrastructure second over commercial growing Our strengthened quarter.
an of rare Importantly, patients polyneuropathic the estimated bringing see a disorder Tegsedi we one access sales hATTR, to in-home largest patients. of have ancestry. the injections markets, to of in XXXX Portuguese Latin because benefit started is Brazil early America treat this has with
as unmet patients Tegsedi market patients bring degree to have need. a of benefit, medical quickly important offers possible. from therapy know as these research high We to And therapeutic
Tegsedi for the Brazil. application the And this, receive expect submitted registration have in year. by of the to We end
Translarna. significant We progress also for made in Brazil
in received age. years the patients for the over regulatory in approval of on Translarna quarter mentioned, five I DMD second As nonsense Brazil, last call, mutation
directly our of to negotiations the the patient received we Health. Brazil. contract approval, Anvisa in approval to This completed broader allow sell now Brazilian access will an Ministry for contract have Having for and annual
access the we in to expanded This expansion is mentioned earlier, five also I label Emflaza patients second years to critical. granted quarter. As old. for two patients our The Emflaza FDA
As can loss delay preserve of And earlier, mass. ambulation. treating patients muscle
well Multiple natural superior that publications from history compared clinical the Prednisone. studies as show product, is as Emflaza long-term data to
grow Our DMD continuing in franchise we revenues. a robust which continues And provides are to produce strong base, to business. the
of quarter. that revenue million, full to $XXX reporting franchise in remain second DMD the million, revenue DMD the in We are XXXX. for was year guidance $XX approximately $XXX our confident We million
also to teams our hard working The been have advance clinical programs.
deficiency a gene potential this AADC and We our year. therapy approval are product, preparing to have to for the track next the on treat submit BLA been BLA with year
be We year. excited to are also NDA, NDA. the oversees end And Roche are effort. the supporting submitted risdiplam expects of that, this the Roche we the by to risdiplam report
increasing oral American Risdiplam results showcased meeting medical overwhelmingly with this Neurology two of Academy and tissue were meetings support broad need an quarter, the was ease therapy, of for distribution. Cure at administration SMA of positive, Meeting. the KOL feedback the with and
SMA targeting space. will to first risdiplam splicing believe program the the therapy competitive most We project apparatus be progression. disease modulate expression the gene demonstrating of specifically the The selectively was that in or course can the SMA change small molecules
small the field. are We modulator the splicing of molecules leaders
splicing to are is FDA an It that proud will Discovering for affect submitted achievement. the drug all the we that accomplishing. be of first something approval small important is molecule to SMA
of We valuable. which have has productive incredibly also investigated risdiplam's and been action, mechanism
we utilized splicing to these a splicing synthesized We to platform molecule small potential treat modulators have discover have efforts other diseases. that to create
with generate the forward, intend patients. transformational new our substantially focus for therapies Moving we to splicing increase to several the on objective platform
by the molecules improve. of competitive continuously hard mechanism that small it a splicing key advantage to modulated and are we how working be can is understanding unique Our
and significant expected drug there we and splicing end for We But next using generate of platform have does disease. another enter the already in produced anticipate FD entering to the candidates the the the clinic for intend clinic a year or soon for platform work coming to within candidate is Familial years. we short, which the Huntington's not dysautonomia number
both Splicing proof modulation FD RNA the blood of the expected in protein be innovation have key tissue HD potential next concept Like and in levels is molecules and to for ability demonstrate show an stakeholders. and allowing source changes early to value to other risdiplam, all and rapid a of the the our year.
You that blood CNS. protein showed clinical may recall for activity in molecules, reflected observed in SMA that of the increases its we the were the levels and
Hopewell, therapy to now that to therapy platform. PTC PTC, priority turn portfolio report our imperative with and are me lease feet access Let Jersey. existing an XXX,XXX facility BMS signed operations which This square research a under biologics includes advance to New and Aligned approximately the buildings of proud gain space. gene to Company, strategic has Squibb Bristol-Myers campus strategic our with agreement infrastructure, state-of-the-art we another production for the gene supporting we long-term on in and
production programs. These this preclinical move located underscore efforts program. adds internal plan the are serve existing to and buildings to BMS plan will of campus. research support We used be to therapy an on research property therapy capacity This gene current and has material further The square our in campus. to building multiple our which also million facility renovated to over commitment clinical biologics recently The a to gene to leasing a same and been multi-tenant operations GMP gene produce site transitioned newly renovated our we existing suites are our develop to New feet, on on the were Jersey. therapy production and to preclinical development Bridgewater, one
and to commercial the clinical progress. I'll Marcio COO, details of the call our Souza, turn now discuss over to our Marcio?
